FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas

Leukemia

Volumn 30, Issue 3, 2016, Pages 605-616

  Brown, P J ^a   Wong, K K ^b   Felce, S L ^a   Lyne, L ^a   Spearman, H ^a   Soilleux, E J ^a   Pedersen, L M ^c   Moller M B ^d   Green, T M ^d   Gascoyne, D M ^a   Banham, A H ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^c ROSKILDE HOSPITAL   (Denmark)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD74 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PREDNISONE; RITUXIMAB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; B LYMPHOCYTE ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP1 PROTEIN, HUMAN; HLA ANTIGEN CLASS 2; INVARIANT CHAIN; MHC CLASS II TRANSACTIVATOR PROTEIN; MONOCLONAL ANTIBODY; NUCLEAR PROTEIN; R-CHOP PROTOCOL; REPRESSOR PROTEIN; SMALL INTERFERING RNA; TRANSACTIVATOR PROTEIN;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL MOTION; CELL SURFACE; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; IMMUNOSURVEILLANCE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VERY ELDERLY; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GERMINAL CENTER; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; MORTALITY; PATHOLOGY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GERMINAL CENTER; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DR ALPHA-CHAINS; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; PREDNISONE; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRANS-ACTIVATORS; VINCRISTINE;

EID: 84959332481     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.299     Document Type: Article

References (59)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511
2. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947
3. Banham AH, Beasley N, Campo E, Fernandez PL, Fidler C, Gatter K, et al. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res 2001; 61: 8820-8829
4. Hu H, Wang B, Borde M, Nardone J, Maika S, Allred L, et al. Foxp1 is an essential transcriptional regulator of B cell development. Nat Immunol 2006; 7: 819-826
5. Koon HB, Ippolito GC, Banham AH, Tucker PW. FOXP1: a potential therapeutic target in cancer. Expert Opin Ther Targets 2007; 11: 955-965
6. Walker MP, Stopford CM, Cederlund M, Fang F, Jahn C, Rabinowitz AD, et al. FOXP1 potentiates Wnt/beta-catenin signaling in diffuse large B cell lymphoma. Sci Signal 2015; 8: 362
7. Wong KK, Gascoyne DM, Brown PJ, Soilleux EJ, Snell C, Chen H, et al. Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-Treated diffuse large B-cell lymphoma patients. Leukemia 2014; 28: 362-372
8. Brown PJ, Ashe SL, Leich E, Burek C, Barrans S, Fenton JA, et al. Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. Blood 2007; 111: 2816-2824
9. Rouhigharabaei L, Ferreiro JF, Tousseyn T, Krogt J-Avd, Put N, Haralambieva E, et al. Non-IG aberrations of FOXP1 in B-cell malignancies lead to an aberrant expression of N-Truncated isoforms of FOXP1. PLoS One 2014; 9: e85851
10. Wang H, Geng J, Wen X, Bi E, Kossenkov AV, Wolf AI, et al. The transcription factor Foxp1 is a critical negative regulator of the differentiation of follicular helper T cells. Nat Immunol 2014; 15: 667-675
11. Tang B, Becanovic K, Desplats PA, Spencer B, Hill AM, Connolly C, et al. Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease. Hum Mol Genet 2012; 21: 3097-3111
12. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105: 1851-1861
13. Rimsza LM, Farinha P, Fuchs DA, Masoudi H, Connors JM, Gascoyne RD. HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen. Leuk Lymphoma 2007; 48: 542-546
14. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-148
15. Chamuleau MED, Ossenkoppele GJ, Loosdrecht AAvd. MHC class II molecules in tumour immunology: prognostic marker and target for immune modulation. Immunobiology 2006; 211: 619-625
16. Higashi M, Tokuhira M, Fujino S, Yamashita T, Abe K, Arai E, et al. Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma. Leuk Lymphoma 2015, 1-6
17. Wilkinson ST, Vanpatten KA, Fernandez DR, Brunhoeber P, Garsha KE, Glinsmann-Gibson BJ, et al. Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma. Blood 2012; 119: 1459-1467
18. Boss JM, Jensen PE. Transcriptional regulation of the MHC class II antigen presentation pathway. Curr Opin Immunol 2003; 15: 105-111
19. Devaiah BN, Singer DS. CIITA and Its Dual Roles in MHC Gene Transcription. Front Immunol 2013; 4: 1-6
20. Reith W, LeibundGut-Landmann S, Waldburger J-M. Regulation of MHC class II gene expression by the class II transactivator. Nat Rev Immunol 2005; 5: 793-806
21. Krawczyk M, Reith W. Regulation of MHC class II expression, a unique regulatory system identified by the study of a primary immunodeficiency disease. Tissue Antigens 2006; 67: 183-197
22. Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011; 471: 377-381
23. Rimsza LM, Chan WC, Gascoyne RD, Campo E, Jaffe ES, Staudt LM, et al. CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression. Haematologica 2009; 94: 596-598
24. Rimsza LM, Roberts RA, Campo E, Grogan TM, Bea S, Salaverria I, et al. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood 2006; 107: 1101-1107
25. Rodo J, Gonçalves LA, Demengeot J, Coutinho A, Penha-Gonçalves C. MHC class II molecules control murine B cell responsiveness to lipopolysaccharide stimulation. J Immunol 2006; 177: 4620-4626
26. Staudt LM, Sandeep D. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol 2005; 87: 163-208
27. Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30: 3460-3467
28. Campbell AJ, Lyne L, Brown PJ, Launchbury RJ, Bignone P, Chi J, et al. Aberrant expression of the neuronal transcription factor FOXP2 in neoplastic plasma cells. Br J Haematol 2010; 149: 221-230
29. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313-2323
30. Roberts R A, Wright G, Rosenwald AR, Jaramillo MA, Grogan TM, Miller TP, et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood 2006; 108: 311-318
31. Riemersma SA, Jordanova ES, Schop RF, Philippo K, Looijenga LH, Schuuring E, et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immuneprivileged sites. Blood 2000; 96: 3569-3577
32. Jordanova ES, Riemersma SA, Philippo K, Giphart-Gassler M, Schuuring E, Kluin PM. Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. Genes Chromosomes Cancer 2002; 35: 38-48
33. Jais JPP, Haioun C, Molina TJ, Rickman DS, de Reynies A, Berger F, et al. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia 2008; 22: 1917-1924
34. Blenk S, Engelmann J, Weniger M, Schultz J, Dittrich M, Rosenwald A, et al. Germinal center B cell-like (GCB) and activated B cell-like (ABC) type of diffuse large B cell lymphoma (DLBCL): analysis of molecular predictors, signatures, cell cycle state and patient survival. Cancer Inform 2007; 3: 399-420
35. Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002; 2: 920-933
36. Rui L, Schmitz R, Ceribelli M, Staudt LM. Malignant pirates of the immune system. Nat Immunol 2011; 12: 933-940
37. Puvvada S, Kendrick S, Rimsza L. Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma. Cancer Genet 2013; 206: 257-265
38. Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, Singh H. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity 2006; 25: 225-236
39. van Keimpema M, Grüneberg LJ, Mokry M, van Boxtel R, Koster J, Coffer PJ, et al. FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-?B to promote survival of human B cells. Blood 2014; 124: 3431-3440
40. Miller TP, Lippman SM, Spier CM, Slymen DJ, Grogan TM. HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. J Clin Invest 1988; 82: 370-372
41. Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel RM, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004; 103: 4251-4258
42. Bernd HW, Ziepert M, Thorns C, Klapper W, Wacker HH, Hummel M, et al. Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma-Analyses of cases from two prospective randomized clinical trials. Haematologica 2009; 94: 1569-1580
43. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282
44. Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, et al A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009; 15: 5494-5502
45. Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 2012; 26: 2103-2113
46. Sagardoy A, Martinez-Ferrandis JI, Roa S, Bunting KL, Aznar MAA, Elemento O, et al. Downregulation of FOXP1 is required during germinal center B-cell function. Blood 2013; 121: 4311-4320
47. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947
48. List AF, Spier CM, Miller TP, Grogan TM. Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence. Leukemia 1993; 7: 398-403
49. Medeiros LJ, Gelb AB, Wolfson K, Doggett R, McGregor B, Cox RS, et al. Major histocompatibility complex class I and class II antigen expression in diffuse large cell and large cell immunoblastic lymphomas. Absence of a correlation between antigen expression and clinical outcome. Am J Pathol 1993; 143: 1086-1097
50. O'Keane JC, Mack C, Lynch E, Harrington D, Neiman RS. Prognostic correlation of HLA-DR expression in large cell lymphoma as determined by LN3 antibody staining. An Eastern Cooperative Oncology Group (ECOG) study. Cancer 1990; 66: 1147-1153
51. Rimsza LM, Leblanc ML, Unger JM, Miller TP, Grogan TM, Persky DO, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008; 112: 3425-3433
52. Craig VJ, Cogliatti SB, Imig J, Renner C, Neuenschwander S, Rehrauer H, et al. Mycmediated repression of microRNA-34a promotes high-grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood 2011; 117: 6227-6236
53. Ott G, Ziepert M, Klapper W, Horn H, Szczepanowski M, Bernd HW, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010; 116: 4916-4925
54. Salles G, de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011; 117: 7070-7078
55. Yamamoto W, Nakamura N, Tomita N, Takeuchi K, Ishii Y, Takahashi H, et al. Human leukocyte antigen-DR expression on flow cytometry and tumorassociated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study. Leuk Lymphoma 2014; 55: 2721-2727
56. Shrestha D, Szoellosi J, Jenei A. Bare lymphocyte syndrome: An opportunity to discover our immune system. Immunol Lett 2012; 141: 147-157
57. Wang B, Weidenfeld J, Lu MM, Maika S, Kuziel WA, Morrisey EE, et al. Foxp1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation. Development 2004; 131: 4477-4487
58. Twa DD, Mottok A, Chan FC, Ben-Neriah S, Woolcock BW, Tan KL, et al. Recurrent genomic rearrangements in primary testicular lymphoma. J Pathol 2015, 136-141
59. Thibodeau J, Bourgeois-Daigneault M-C, Lapointe R. Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy. Oncoimmunology 2012; 1: 908-916